CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant.
Bone marrow and blood demonstrate distinct immune reconstitution patterns and correlations with relapse posttransplant.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
骨髓是许多血液系统恶性肿瘤的肿瘤微环境,也是造血移植后同种免疫的一个潜在关键部位。尽管移植后免疫重建(IR)十分重要,但骨髓IR数据有限,相关认识主要来源于外周血(PB)研究。
我们对因血液系统恶性肿瘤接受异基因移植的成人(n = 33)的骨髓(n = 110)和外周血样本(n = 115)进行了淋巴细胞IR的纵向研究。该移植队列涵盖了多种移植物来源(动员外周血、CD34筛选移植物和脐带血)及不同程度的HLA错配。自然杀伤(NK)细胞在移植后前30天内在骨髓和外周血中均快速扩增,但100天后在外周血中被T细胞数量超越。相比之下,NK细胞在第100天时在骨髓中仍占主导地位(P < .01,配对Wilcoxon符号秩检验),此后第1年内骨髓中T细胞和NK细胞频率相近。移植后的组织特异性特征包括:与外周血相比,骨髓中调节性T细胞更少、固有淋巴细胞更多、淋巴细胞上CD69表达增加。
此外,第100天时骨髓T细胞上PD1(程序性细胞死亡蛋白1)的表达在未复发患者中高于随后复发的患者。这些发现揭示了移植后早期骨髓中NK细胞持续占主导地位,并提示骨髓免疫与临床移植结局之间存在相关性。
The bone marrow represents the tumor microenvironment for many hematologic malignancies and a potentially critical site for alloimmunity after hematopoietic transplantation. Despite the importance of immune reconstitution (IR) after transplant, marrow IR data are limited, and insights are largely derived from studies of peripheral blood (PB).
We investigated lymphocyte IR longitudinally in marrow (n = 110) and PB samples (n = 115) from adults undergoing allogeneic transplantation for hematologic malignancies (n = 33). This transplant cohort included a diverse representation of graft sources (mobilized PB, CD34-selected grafts, and umbilical cord blood) and degrees of HLA mismatch. Natural killer (NK) cells quickly expanded within the first 30 days after transplant in both the marrow and PB, but were then outnumbered by T cells in PB after day 100.
In contrast, NK cells remained dominant in the marrow at day 100 (P < . 01, paired Wilcoxon signed-rank test), and thereafter marrow T and NK cell frequencies were similar throughout year 1. Tissue-specific features after transplant included fewer regulatory T cells, more innate lymphoid cells, and increased CD69 expression on lymphocytes in the marrow compared with PB.
Furthermore, day 100 PD1 (programmed cell death protein 1) expression on marrow T cells was greater in nonrelapsing patients than those who subsequently relapsed.
These findings reveal persistent NK dominance of the marrow early after transplant and suggest correlations between marrow immunity and clinical transplant outcomes.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。